EFFECTS OF MICROBIOTES ON THE DEVELOPMENT OF HUMAN TUMOR PATHOLOGIES
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-22-1-2020-g.8759Keywords:
cancer, chemotherapy, immunotherapy, microbiota, tumor-microbiota interactionAbstract
The presented review analyzes and summarizes modern scientific data on the key mechanisms by which the microbiota of bacterial origin affects the tumor process and the effectiveness of antitumor therapy. Modern genome research technologies have made it possible to implement the Human Microbiome Project (2008–2013). Thanks to this project, updated data on the number and variety of microbiota composition of the human body were obtained. It is also known that a number of human pathologies, including inflammatory bowel disease, metabolic diseases, allergic and autoimmune pathologies, cardiovascular diseases, neurodegenerative diseases and mental disorders, as well as oncological processes are associated with certain species compositions of intestinal microbiota. Current data on the mechanisms by which certain species of bacteria promote the formation or inhibition of human and experimental tumors are presented. In addition, it has been proven that the metabolic activity of the microbiota affects the effectiveness of chemotherapy, radiotherapy and immunotherapy in malignant growth. Assessment of the microbiota provides important information for predicting the aggressiveness of the tumor process and the sensitivity of the tumor to therapy. Since diet is a key factor influencing the composition and function of the microbiota, the development of individual dietary programs for cancer patients is one of the priorities of modern clinical observations.
References
Huse S, Ye Y, Zhou Y, Fodor A. A Core human microbiome as viewed through 16s rrna sequence clusters. PLoS ONE 2012; 7 (6): 1–12.
Сho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13 (4): 260–70.
Zou Y, Xue W, Luo G, et al. 1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses. Nat Biotechnol 2019; 37 (2): 179–85.
Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev Microbiol 2018; 16 (3): 143–55.
Rowan-Nash AD, Korry BJ, Mylonakis E, et al. Cross-domain and viral interactions in the microbiome. Microbiol Mol Biol Rev 2019; 83 (1): 1–63.
Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 2016; 164 (3): 337–40.
Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: dynamic communities and host interactions. Nat Rev Microbiol 2018; 16 (12): 745–59.
Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol 2015; 15 (1): 30–44.
Pieczynska MD, Yang Y, Petrykowski S, et al. Gut microbiota and its metabolites in atherosclerosis development. Molecules 2020; 25 (3): 594.
Dinan TG, Cryan GF. Microbes, immunity, and behavior: psychoneuroimmunology meets the microbiome. Neuropsychopharmacology 2017; 42 (1): 178–92.
Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 2018; 23 (6): 716–24.
Zitvogel L, Daillère R, Roberti MP, et al. Anticancer effects of the microbiome and its products. Nat Rev Microbiol 2017; 15 (8):465–78.
Gagnaire A, Nadel B, Raoult D, et al. Collateral damage: insights into bacterial mechanisms that predispose host cells to cancer. Nat Rev Microbiol 2017; 15 (2): 109–28.
Garrett WS. Cancer and the microbiota. Science 2015; 348 (6230): 80–86.
Roesler BM, Rabelo-Gonçalves EMA, Zeitune JMR. Virulence factors of helicobacter pylori: a review. Clinical Medicine Insights: Gastroenterology 2014; 7: 9–17.
Plottel CS, Blaser MJ. Microbiome and malignancy. Cell Host Microbe 2011; 10 (4): 324–35.
Godoy-Vitorino F. Human microbial ecology and the rising new medicine. Ann Transl Med 2019; 7 (14): 342.
Wu J, Li Q, Fu X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity. Transl Oncol 2019; 12 (6): 846–51.
Shang FM, Liu HL. Fusobacterium nucleatum and colorectal cancer: a review. World J Gastrointest Oncol 2018; 10 (3): 71–81.
Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, et al. WNT signaling in tumors: The way to evade drugs and immunity. Front Immunol 2019; 10: 2854.
Karpi´nski TM. Role of oral microbiota in cancer development. Microorganisms 2019; 7 (1): 20.
Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499 (7456): 97–101.
Fernández MF, Reina-Pérez I, Astorga JM, et al. Breast cancer and its relationship with the microbiota. Int J Environ Res Public Health 2018; 15 (8): 1747.
Li Z, Quan G, Jiang X, et al. Effects of Metabolites Derived From Gut Microbiota and Hosts on Pathogens. Front Cell Infect Microbiol 2018; 8: 314.
Zhao H, Yu Z, Zhao L, He M, et al. HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy. Jpn J Clin Oncol 2016; 46(10): 893–902.
Gately S. Human microbiota and personalized cancer treatments: role of commensal microbes in treatment outcomes for cancer patients. Cancer Treat Res 2019; 178: 253–64.
Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 2015; 350 (6264): 1084–9.
Zhuo Q, Yu B, Zhou J, et al. Lysates of Lactobacillus acidophilus combined with CTLA-4-blocking antibodies enhance antitumor immunity in a mouse colon cancer. Sci Rep 2019; 9 (1): 20128.
Deleemans JM, Chleilat F, Reimer RA, et al. The chemo-gut study: investigating the long-term effects of chemotherapy on gut microbiota, metabolic, immune, psychological and cognitive parameters in young adult Cancer survivors; study protocol. BMC Cancer 2019; 19 (1): 1243.
Zitvogel L, Ayyoub M, Routy B, et al. Microbiome and anticancer immunosurveillance. Cell 2016; 165 (2): 276–87.
Boursi B, Mamtani R, Haynes K, et al. Recurrent antibiotic exposure may promote cancer formation — another step in understanding the role of the human microbiota. Eur J Cancer 2015; 51 (17): 2655–64.
McKee AM, Lindsay J, Hall LJ, et al. The microbiota, antibiotics and breast cancer. Breast Сancer Manag 2019; 8 (3): BMT29.
Viaud S, Flament C, Zoubir M, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 2011; 71 (3): 661–5.
Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342 (6161): 971–6.
Uribe-Herranz M, Rafail S, Koumenis C, et al. Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response. J Clin Invest 2020; 130 (1): 466–79.
Abid M B, Shah NN, Maatman TC, et al. Gut microbiome and CAR-T therapy. Exp Hematol Oncol 2019; 8: 3.
Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350 (6264): 1079–84.
Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 2015; 350 (6264): 1084–9.
Macchione IG, Lopetuso LR, Ianiro G, et al. Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders. Eur Rev Med Pharmacol Sci 2019; 23 (18): 8075–83.
Illiano P, Brambilla R, Parolini C. The mu tual interplay of gut microbiota, diet and human disease. FEBS J 2020; 287 (5): 833–55.
Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Іmmunol 2017; 18 (8): 843–50.
Chen D, Wu J, Jin D, et al. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer 2019; 145 (8): 2021–31.
